Second-line treatment of postmenopausal women with advanced breast carcinoma.
AffiliationCancer Research UK Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractBreast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab.
CitationSecond-line treatment of postmenopausal women with advanced breast carcinoma. 2006, 6 (4):613-24 Expert Rev Anticancer Ther
JournalExpert Review of Anticancer Therapy
- Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.
- Authors: Briest S, Wolff AC
- Issue date: 2007 Sep
- Hormonal therapy for advanced breast cancer.
- Authors: Rugo HS
- Issue date: 2007 Apr
- Targeted therapies in breast cancer.
- Authors: Tripathy D
- Issue date: 2005 Mar-Apr
- Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
- Authors: Gligorov J, Lotz JP
- Issue date: 2008 Dec
- Target-based therapies in breast cancer: current status and future perspectives.
- Authors: Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F
- Issue date: 2009 Sep